Evaluation of efficacy and safety of bilastine 20 mg tablets in adult patients with allergic rhinitis

Authors

  • Samir Bhargava Bhargava Nursing Home, Santacruz (W), Mumbai, Maharashtra, India
  • Karthikeyan Padmanabhan Mahatma Gandhi Medical College and Research Institute, Puducherry, India
  • Chidananda Ramappa Medstar Speciality Hospital, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20223077

Keywords:

Bilastine, Allergic rhinitis, NNTSS, NSS, ROLQ

Abstract

Background: Bilastine is a nonsedating, H1-antihistamine used for symptomatic treatment of allergic rhinitis; However, data on its efficacy and safety in Indian patients with allergic rhinitis are lacking.

Methods: In this multicenter, single-arm, investigator-initiated study, 90 patients with allergic rhinitis received bilastine 20 mg tablets once daily for 4 weeks. The primary endpoint was change in total symptom score (TSS=nasal symptom score [NSS] + non-nasal symptom score [NNSS]) at day 28 from baseline. Severity of individual nasal and non-nasal symptoms was assessed at baseline, day 7, and day 28 by rating each symptom on a scale of 0-3. Key secondary endpoints were incidence of treatment-emergent adverse events (TEAEs), changes in NSS, NNSS, and rhinoconjunctivitis quality of life questionnaire (RQLQ) score, and from baseline to days 7 and 28, and change in Stanford sleepiness scale (SSS) score from baseline to 2 hours post-first dose.

Results: The mean allergic rhinitis symptom scores TSS, NSS and NNSS showed a significant decrease (p˂0.0001) at each visit compared with baseline. A statistically significant decline (p˂0.0001) in the mean RQLQ score was observed at days 7 and 28 versus baseline. Median SSS score was 1.0 (range: 1.0-7.0) before and after the 1st dose of bilastine, indicating that it did not cause sedation. No TEAEs were reported during the study.

Conclusions: Bilastine 20 mg once daily was efficacious in reducing nasal and non-nasal allergic symptoms, was well tolerated, and had a good safety profile in patients with allergic rhinitis.

References

Klimek L, Bachert C, Pfaar O, Becker S, Bieber T, Brehler R et al. ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergol Select 2019;3:22-50.

World Allergy Organization (WAO) white book on allergy, 2011. Available at https://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf. Accessed on 25 Oct, 2022.

Varshney J, Varshney H. Allergic rhinitis: an overview. Ind J Otolaryngol Head Neck Surg. 2015;67:143-9.

Singh S, Sharma BB, Salvi S, Chhatwal J, Jain KC, Kumar L. Allergic rhinitis, rhinoconjunctivitis, and eczema: prevalence and associated factors in children. Clin Respir J. 2018;12(2):547-56.

Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108:S45-53.

Enna SJ, Bylund DB. XPharm: The Comprehensive Pharmacology Reference. (Enna SJ, Bylund DB, eds.). 1st ed. Amsterdam: Elsevier; 2008.

Small P, Frenkiel S, Becker A, Boisvert P, Bouchard J, Carr et al. Rhinitis: A practical and comprehensive approach to assessment and therapy. J Otolaryngol. 2007;36:S5.

Kim H, Kaplan A. Treatment and management of allergic rhinitis [feature]. Clin Focus. 2008;1-4.

Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63:1292-300.

Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466-476.

Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. J Otolaryngology. 2008;29:403-13.

Sur DKC, Plesa ML. Treatment of allergic rhinitis. Am Fam Physician. 2015;92:985-92.

Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015;152:197-206.

Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019;20:213.

Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet. 2009;48:543-54.

Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011;10:779-93.

Antonijoan R, Coimbra J, García-Gea C, Puntes M, Gich I, Campo C et al. Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers. Curr Med Res Opin. 2016;33:129-36.

Togawa M, Yamaya H, Rodríguez M, Nagashima H. Pharmacokinetics, pharmacodynamics and population pharmacokinetic/pharmacodynamic modelling of bilastine, a second-generation antihistamine, in healthy Japanese subjects. Clin Drug Invest. 2016;36:1011-21.

Church MK. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res. 2011;60:1107-12.

Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010;59:391-8.

Sádaba B, Gómez-Guiu A, Azanza JR, Ortega I, Valiente R. Oral availability of bilastine. Clin Drug Investig. 2013;33:375-81.

Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C et al. Allergic rhinitis and its impact on asthma (ARIA): Achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130:1049-62.

García-Gea C, Martínez J, Ballester MR, Gich I, Valiente R, Antonijoan RM. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol. 2014;29:120-32.

Bousquet J, Ansotegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012;28:131-9.

Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al. Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868-87.

Okubo K, Gotoh M, Asako M, Nomura Y, Togawa M, Saito A et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int. 2017;66:97-105.

Randhawa AS, Noor NM, Daud MKM, Abdullah B. Efficacy and safety of bilastine in the treatment of allergic rhinitis: A systematic review and meta-analysis. Front Pharmacol. 2022;12:731201.

Hoddes E, Dement W, Zarcone V. Abstracts of papers presented to the eleventh annual meeting of the Association for the Psychophysiological Study of Sleep: the development and use of the Stanford sleepiness scale (SSS). Psychophysiology. 1972;9:150.

Church MK, Tiongco-Recto M, Ridolo E, Novák Z. Bilastine: A lifetime companion for the treatment of allergies. Curr Med Res Opin. 2019;36:445-54.

Sastre J, Mullol J, Valero A, Valiente R. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin. 2012;28:121-30.

Lynde CW, Sussman G, Dion PL, Guenther L, Hébert J, Rao J et al. Multidisciplinary real-world experience with bilastine, a second-generation antihistamine. J. Drugs Dermatol. 2020;19:145-54.

Downloads

Published

2022-11-25

How to Cite

Bhargava, S., Padmanabhan, K., & Ramappa, C. (2022). Evaluation of efficacy and safety of bilastine 20 mg tablets in adult patients with allergic rhinitis. International Journal of Research in Medical Sciences, 10(12), 2769–2775. https://doi.org/10.18203/2320-6012.ijrms20223077

Issue

Section

Original Research Articles